<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(12)</volume><submitter>Racke FK</submitter><pubmed_abstract>Thrombopoiesis following severe bone marrow injury frequently is delayed, thereby resulting in life-threatening thrombocytopenia for which there are limited treatment options. The reasons for these delays in recovery are not well understood. Protein kinase C (PKC) agonists promote megakaryocyte differentiation in leukemia cell lines and primary cells. However, little is known about the megakaryopoietic effects of PKC agonists on primary CD34+ cells grown in culture or in vivo. Here we present evidence that the novel PKC isoform-selective agonist 3,20 ingenol dibenzoate (IDB) potently stimulates early megakaryopoiesis of human CD34+ cells. In contrast, broad spectrum PKC agonists failed to do so. In vivo, a single intraperitoneal injection of IDB selectively increased platelets in mice with</pubmed_abstract><journal>PloS one</journal><pagination>e51059</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3528756</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist.</pubmed_title><pmcid>PMC3528756</pmcid><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Rutledge H</pubmed_authors><pubmed_authors>Baird M</pubmed_authors><pubmed_authors>Racke FK</pubmed_authors><pubmed_authors>Barth RF</pubmed_authors><pubmed_authors>Huo T</pubmed_authors><pubmed_authors>Gupta N</pubmed_authors><pubmed_authors>Weldon M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist.</name><description>Thrombopoiesis following severe bone marrow injury frequently is delayed, thereby resulting in life-threatening thrombocytopenia for which there are limited treatment options. The reasons for these delays in recovery are not well understood. Protein kinase C (PKC) agonists promote megakaryocyte differentiation in leukemia cell lines and primary cells. However, little is known about the megakaryopoietic effects of PKC agonists on primary CD34+ cells grown in culture or in vivo. Here we present evidence that the novel PKC isoform-selective agonist 3,20 ingenol dibenzoate (IDB) potently stimulates early megakaryopoiesis of human CD34+ cells. In contrast, broad spectrum PKC agonists failed to do so. In vivo, a single intraperitoneal injection of IDB selectively increased platelets in mice with</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012</publication><modification>2025-05-31T22:54:17.491Z</modification><creation>2025-05-31T22:54:17.491Z</creation></dates><accession>S-EPMC3528756</accession><cross_references><pubmed>23284657</pubmed><doi>10.1371/journal.pone.0051059</doi></cross_references></HashMap>